Needle-Free Drug Injection Systems and Safety Syringes: A Global Strategic Business Report
San Jose, California (PRWEB) July 19, 2012
Follow us on LinkedIn – Injections are designed to deliver a drug to a patient to treat a particular condition. However, these can themselves become a source of new problems, mainly in the form of accidental needlestick injuries to workers at healthcare institutions. Some of these injuries could be detrimental as they aid in transfer of blood borne pathogens from an affected patient to a healthy caregiver. Major pathogens transmitted this way include HCV, HBV and HIC. Needlestick injuries can have a significant emotional impact on the subjects, even in cases where no serious infections are transmitted. Several types of needles are employed in a healthcare environment for providing treatment to patients. Not all needles, however, are known to cause or be a reason for needlestick injuries. Generally, blood collection needles, needles employed in IV delivery, hypodermic needles, and suture needles are the most common forms of needles involved in such injuries. Recapping of needles, transfer of body fluid from one container to another and failure in the proper disposal of used needles among other work practices enhance risk for needlestick injuries.
Drug delivery of modern day medicine has long been dominated by potions and pills, which currently is undergoing a shift towards more advanced drug delivery. Not only are newer drug delivery systems safer but also are more effective than the conventional approaches. The novel drug delivery methods include safety syringes and needle-free injections. Development of these systems has been driven mainly by factors such as pain-free administration of injections such as in needle-free systems, enhanced safety for patient and caregivers through safety syringes, and increasing regulations dictating practices in healthcare work environment among others. Needle-free injection and safety syringes initially failed to live up to their potential since being introduced in the middle of the 20th century, due mostly to the poor quality, design issues, as well as weak management. However, adoption of these syringes began to surge in the recent years thanks to emergence of innovative and affordable products in the market.
Majority of the drugs including peptides, insulin, hormones and proteins are destroyed by oral administration, and subsequently require parenteral delivery. Ongoing research in the field of new drug delivery systems would help in fueling the market growth of needle-free transdermal, oral and inhaled approaches. Those engaged in the development of needle-free devices have acknowledged the weaknesses and drawbacks of the drug-delivery system and are undertaking research for upgrading the technology to enable further market expansion. The market for these devices is expected to surge as more and more drugs are being developed, which are designed for being delivered through needle-free systems. The future for needle-free injection systems appears bright. Continued efforts to minimize needle stick injuries and to provide painless injection delivery are expected to support future growth in the market. Several new products, currently development, are also expected to take innovation and safety to a new level, further encouraging adoption.
As the drive towards safer injection of medication surges further, demand for pre-filled syringes is expected to witness substantial growth in the years ahead. Factors such as design enhancements, increased acceptance of benefits offered by the syringes to patients and caregivers, and maturing supply chain are all ensuring continued rapid rise in demand for pre-filled syringes, especially in volume terms. Efforts to enhance safety for caregivers and patients are also rendering advancements in options for packaging and delivery of drugs. These advancements hold potential to eliminate the need for drug preparation and handling activities that are known to be the major sources of needlestick injuries and dosing errors. Pre-filled syringes offer tremendous benefits such as improved patient compliance, a factor which is also instrumental in surging demand for these products. The huge number of biologic drugs emerging in the market is also offering tremendous opportunities for pre-filled syringes. For biological drugs, these syringes offer significant economies given the higher cost of biological drugs. Pharmaceutical companies, manufacturers of pre-filled syringes, regulators and consumers are all benefiting from use of pre-filled syringes.
Although, safety syringes have succeeded in reducing the number of accidental pricks in the markets where these syringes have been adopted at a significant scale, they have not totally eliminated accidental injuries to caregivers. Safety syringe technologies now available in the market have not been successful in providing optimal protection to workers in the healthcare environment, especially in alleviating incidents accidental transmission of blood-borne pathogens to healthcare workers. In the US, for instance, introduction safety syringes post regulatory mandates, have helped in stabilizing the number of such incidents occurring each year. However, a peek into this data reveals that most needlestick injuries being recorded now emerge from syringes that are equipped with some kind of safety feature. Consequently, need for further advancements in safety features is required to achieve declines in incidents of needlestick injuries.
The US represents the largest regional market worldwide, as stated by the new market research report on Needle-Free Drug Injection Systems and Safety Syringes. Demand for these products in the US market is being driven by substantial growth in demand for biotechnology drugs that demand use of novel drug delivery technologies such as sustained release and targeted-injection. However, Europe is projected to emerge as the fastest growing regional market for Needle-Free Drug Injection Systems and Safety Syringes, trailing a compounded annual growth rate of close to 30% during the analysis period 2010-2018.
Major players profiled in the report include 5iPrinicipals Group, LLC, Bector, Dickinson, BioValve Technologies, Inc., Covidien Plc, Incline Therapeutics, Inc., PenJet Corporation, Retractable Technologies, Inc., Safety Syringes, Inc., Unilife Medical Solutions Ltd., Zogenix, Inc., among others.
The research report titled “Needle-Free Drug Injection Systems and Safety Syringes: A Global Strategic Business Report” announced by Global Industry Analysts, Inc., provides comprehensive market overview, trends & issues, recent product innovations/introductions, recent industry activity and profiles of leading market players. Analysis and overview is provided for the years 2010 through 2018, for major geographic markets, such as the US, Canada, Japan, Europe, Asia-Pacific and Rest of World. Market analytics for Needle-Free Drug Injection Systems and Safety Syringes are provided for global and regional markets in US$ Million. The study also provides historic data for an insight into market evolution over the period 2004 through 2009.
For more details about this comprehensive market research report, please visit –
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/